MYEF2

Across TCGA pan-cancer cohorts, MYEF2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYEF2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MYEF2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MYEF2 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where MYEF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.646	0.240	<.001	22	view →
PDAC	OS	Tertile	III,IV	0.944	0.441	.008	19	view →
CCRCC	OS	Median	All	0.958	0.843	.032	15	view →
LUAD	OS	Median	II,III,IV	0.792	0.468	.010	10	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYEF2–GBM (OS)

Open the GBM breakdown →